42461-84-7 Usage
Description
Flunixin meglumin is a nonsteroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class of NSAIDs. It is used for its anti-inflammatory, analgesic, and antipyretic properties. Flunixin meglumin is particularly effective in treating inflammation and pain associated with various conditions, including dental carries and other inflammatory disorders.
Uses
Used in Veterinary Medicine:
Flunixin meglumin is used as an anti-inflammatory and analgesic agent for the treatment of pain and inflammation in animals, particularly in horses and cattle. It helps to alleviate discomfort and reduce inflammation associated with various conditions, such as musculoskeletal disorders, soft tissue injuries, and post-operative pain.
Used in Dental Care:
Flunixin meglumin is used as a prophylactic agent in dental carries treatment. It helps to reduce inflammation and pain associated with dental carries, promoting a more comfortable and effective treatment process.
Used in Mass Spectrometry:
Flunixin meglumin has been used as a nonsteroidal anti-inflammatory drug standard in electrospray ionization mass spectrometry (LC-ESI/MS). This application allows for the accurate identification and quantification of Flunixin meglumin in various samples, ensuring the quality and consistency of the drug.
Used as a Cyclooxygenase Inhibitor:
Flunixin meglumin functions as a cyclooxygenase inhibitor, which plays a crucial role in the inhibition of prostaglandin synthesis. This action contributes to its anti-inflammatory, analgesic, and antipyretic effects, making it a valuable drug for the management of various inflammatory and painful conditions.
Biological Activity
flunixin meglumine serves as a non-narcotic and non-steroidal analgesic agent with antipyretic activities. as a potent inhibitor of the enzyme cyclooxygenase, flunixin meglumine has demonstrated a wide-spectrum of biological activities including anti-inflammation and pain-alleviating. moreover, flunixin meglumine could be applied as a drug in animals for the management of intestinal ischaemia, colic, and endotoxemia. [1]
Biochem/physiol Actions
COX1, COX2 and PLA2 inhibitor non-narcotic analgesic, anti-pyretic, anti-inflammatory.
Veterinary Drugs and Treatments
In the United States, flunixin meglumine is approved for use in
horses, cattle
and swine; however, it is approved for use in dogs in
other countries. The approved indications for its use in the horse
are for the alleviation of inflammation and pain associated with
musculoskeletal disorders and alleviation of visceral pain associated
with colic. In cattle it is approved for the control of pyrexia
associated with bovine respiratory disease and endotoxemia, and
control of inflammation
in endotoxemia. In swine, flunixin is approved
for use to control pyrexia associated with swine respiratory
disease.
Flunixin has been suggested for many other indications in various
species, including: Horses: foal diarrheas,
shock, colitis, respiratory
disease, post-race treatment, and pre- and post ophthalmic
and general
surgery; Dogs: disk problems, arthritis, heat stroke, diarrhea,
shock, ophthalmic inflammatory conditions, pre- and post
ophthalmic and general surgery, and treatment of parvovirus infection;
Cattle: acute respiratory disease, acute coliform mastitis with
endotoxic shock, pain (downer cow), and calf diarrheas; Swine:
agalactia/hypogalactia, lameness, and piglet diarrhea. It should be
noted that the evidence
supporting some of these indications is
equivocal and flunixin may not be appropriate for every case.
in vitro
an in vitro whole blood model in feedlot calves was adopted to detect the activity of the anti-inflammatory agents flunixin-meglumine (flu), rs (±) carprofen (cpf) and s (+) cpf. the drugs all exhibited inhibitory activity on coxs, with an order of flu > s (+) cpf > rs (±) cpf in their potency. this finding indicated that flu was a nonselective suppressorr of bovine coxs, whereas rs (±) cpf and s (+) cpf selectively inhibited cox-2 isoenzyme. [2]
in vivo
findings from mice, rats and monkeys suggested flunixin meglumine as a potent non-narcotic analgesic agent after parenteral administration. after being subcutaneous administered, this agent showed higher efficacy than pentazocine, meperidine and codeine in the rat yeast paw test. intramuscular administration and subcutaneous administration of flunixin meglumine had similar effects. moreover, orally administered flunixin meglumine also exerted analgesic and anti-inflammatory activities. based on mice abdominal constriction test, flunixin meglumine had comparable efficacy to pentazocine and was more potent than meperidine and codeine. in primates, 10 mg/kg flunixin meglumine showed an equal efficacy to that of 0.3 mg/kg morphine. [1]
IC 50
a potent cyclooxygenase inhibitor with ic50 values of 1 nm.
references
[1]ciofalo vb, latranyi mb, patel jb and taber ri. flunixin meglumine: a non-narcotic analgesic. j pharmacol exp ther. 1977 mar; 200(3): 501-7.[2]miciletta m, cuniberti b, barbero r and re g. in vitro enantioselective pharmacodynamics of carprofen and flunixin-meglumine in feedlot cattle. j vet pharmacol ther. 2014 feb; 37(1): 43-52. [3] jochle w, moore jn, brown j, baker gj, lowe je, fubini s, reeves mj, watkins jp and white na. comparison of detomidine, butorphanol, flunixin meglumine and xylazine in clinical cases of equine colic. equine vet j suppl. 1989 jun; (7): 111-6.
Check Digit Verification of cas no
The CAS Registry Mumber 42461-84-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,4,6 and 1 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 42461-84:
(7*4)+(6*2)+(5*4)+(4*6)+(3*1)+(2*8)+(1*4)=107
107 % 10 = 7
So 42461-84-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H11F3N2O2.C7H17NO5/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-7H,1H3,(H,18,19)(H,20,21);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
42461-84-7Relevant articles and documents
Preparation method of flunixin meglumine
-
Paragraph 0022; 0025; 0038-0041; 0046-0053, (2019/01/24)
The invention discloses a preparation method of flunixin meglumine the preparation method, and the method specifically comprises the following steps: (1) adding 2-chloronicotinic acid and 2-methyl-3-trifluoromethyl aniline into a sodium hydroxide water solution for stirring, adding ethylene glycol as well as a phase transfer catalyst and p-toluenesulfonic acid and copper oxide, controlling the temperature and time, adjusting the pH value of the solution, stirring, standing, layering, stirring, filtering, washing filter cake, and drying to obtain flunixin; and (2) reacting the flunixin obtainedin the step (1) with N-methylglucosamine in isopropyl alcohol, and meanwhile, adding a filler; carrying out heating reflux, filtering, cooling, stirring and crystallizing, carrying out crystal suction filtration, and washing crystals with isopropanol to obtain the flunixin meglumine. The preparation method of the flunixin meglumine is convenient and simple in operation, the reflecting efficiencyis high, the reaction temperature is low, the reaction time is short, and the cost is low; moreover, the prepared flunixin meglumine is high in purity and high in yield.